Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s ...
“We can probably edit almost any gene, but that doesn’t mean we should,” Dan Rosan, chief financial and business officer of Ascidian Therapeutics, told Fierce Biotech. That thinking has shaped how the ...
Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The ...
NewLimit’s lead liver combo has proven its worth in preclinical models, Kimmel told Fierce, with the ability to boost ...
British medtech startup IMU Biosciences has landed a £40 million ($53 million) series A as it looks to move immune system analysis from analogue to “high definition.” The London-based company was ...
Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific ...
A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 ...
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug ...
With Innovent Biologics garnering buzz in the dealmaking space, Ta | Takeda and Innovent's long-term follow-up data from an ...
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following ...
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a ...
In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results